##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, DC 20549
 
 FORM 10-Q
 (Mark One)
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended June 30, 2010
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from  to
 Commission file number: 0-24274
 LA JOLLA PHARMACEUTICAL COMPANY
  Delaware
    
    33-0361285(State or other jurisdiction of
    
    (I.R.S. Employerincorporation or organization)
    
    Identification No.)4365 Executive Drive, Suite 300San Diego, CA
    
    92121(Address of principal executive offices)
    
    (Zip Code)
  Yes þ No o
 Yes o No o
  Large accelerated filer o
    
    Accelerated filer o
    
    Non-accelerated filer o
    
    Smaller reporting company þ
 Yes o No þ




---



##### 



LA JOLLA PHARMACEUTICAL COMPANY
FORM 10-Q
QUARTERLY REPORT
 INDEX
 PART I. FINANCIAL INFORMATIONITEM 1. Condensed Financial Statements  UnauditedCondensed Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009
    
    
    1Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2010 and 2009
    
    
    2Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2010 and 2009
    
    
    3Notes to Condensed Consolidated Financial Statements
    
    
    4ITEM 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    19ITEM 4. Controls and Procedures
    
    
    23PART II. OTHER INFORMATIONITEM 1A. Risk Factors
    
    
    24ITEM 6. Exhibits
    
    
    28SIGNATURES
    
    
    29Exhibit 31.1Exhibit 31.2Exhibit 32.1




---



##### Table of Contents



PART I. FINANCIAL INFORMATION
 
 ITEM 1. CONDENSED FINANCIAL STATEMENTS  UNAUDITED
 LA JOLLA PHARMACEUTICAL COMPANY
 
 Condensed Consolidated Balance Sheets
  June 30,
    
    
    December 31,2010
    
    
    2009(Unaudited)
    
    
    (See Note)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    8,071
    
    
    $
    4,254Prepaids and other current assets
    
    
    150
    
    
    
    586Total current assets
    
    
    8,221
    
    
    
    4,840Total assets
    
    $
    8,221
    
    
    $
    4,840LIABILITIES,
REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS (DEFICIT) EQUITYCurrent liabilities:Accounts payable
    
    $
    87
    
    
    $
    125Accrued expenses
    
    
    328
    
    
    
    323Accrued payroll and related expenses
    
    
    109
    
    
    
    173Derivative liabilities
    
    
    8,103
    
    
    
    Total current liabilities
    
    
    8,627
    
    
    
    621Series C-1 redeemable convertible preferred stock,
$0.01 par value; 11,000 shares authorized, 5,184 and no
shares issued and outstanding at June 30, 2010 and
December 31, 2009, respectively (redemption value and
liquidation preference in the aggregate of
$5,258 at June 30, 2010)
    
    
    29
    
    
    
    CommitmentsStockholders (deficit) equity:Common stock, $0.01 par value; 225,000,000 shares
authorized, 94,693,083 and 65,722,648 shares issued and
outstanding at June 30, 2010 and December 31, 2009
    
    
    947
    
    
    
    657Additional paid-in capital
    
    
    427,810
    
    
    
    427,883Accumulated deficit
    
    
    (429,192
    )
    
    
    (424,321
    )Total stockholders (deficit) equity
    
    
    (435
    )
    
    
    4,219Total
liabilities, redeemable convertible preferred stock and stockholders (deficit) equity
    
    $
    8,221
    
    
    $
    4,840
 Note:
    
    The condensed consolidated balance sheet at December 31, 2009 has been derived from the
audited consolidated financial statements as of that date but does not include all of the
information and disclosures required by U.S. generally accepted accounting principles.   1




---



##### Table of Contents



LA JOLLA PHARMACEUTICAL COMPANY
 
 Condensed Consolidated Statements of Operations
   Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,2010
    
    
    2009
    
    
    2010
    
    
    2009Revenue from collaboration
agreement
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    8,125Expenses:Research and development
    
    
    9
    
    
    
    (85
    )
    
    
    9
    
    
    
    9,808General and administrative
    
    
    901
    
    
    
    2,124
    
    
    
    2,667
    
    
    
    4,611Total expenses
    
    
    910
    
    
    
    2,039
    
    
    
    2,676
    
    
    
    14,419Loss from operations
    
    
    (910
    )
    
    
    (2,039
    )
    
    
    (2,676
    )
    
    
    (6,294
    )Other income (expense):Fair value of derivative
liabilities upon issuance
    
    
    (5,015
    )
    
    
    
    
    
    
    (5,015
    )
    
    
    Adjustments to fair value
of derivative liabilities
    
    
    2,985
    
    
    
    
    
    
    
    2,985
    
    
    
    Financing transaction costs
    
    
    (164
    )
    
    
    
    
    
    
    (164
    )
    
    
    Interest income and other
expense, net
    
    
    
    
    
    
    (4
    )
    
    
    (1
    )
    
    
    (1
    )Net loss
    
    
    (3,104
    )
    
    
    (2,043
    )
    
    
    (4,871
    )
    
    
    (6,295
    )Preferred stock dividend
    
    
    (87
    )
    
    
    
   
    
    
    (87
    )
    
    
    Net loss and comprehensive loss attributable to common stockholders
    
    $
    (3,191
    )
    
    $
    (2,043
   )
    
    $
    (4,958
   )
    
    $
    (6,295
   )Basic and diluted net loss per
share
    
    $
    (0.04
    )
    
    $
    (0.03
    )
    
    $
    (0.07
    )
    
    $
    (0.10
    )Shares used in computing basic
and diluted net loss per share
    
    
    77,183
    
    
    
    65,723
    
    
    
    71,485
    
    
    
    60,945
   2




---



##### Table of Contents



LA JOLLA PHARMACEUTICAL COMPANY
 
 Condensed Consolidated Statements of Cash Flows
   Six Months EndedJune 30,2010
    
    
    2009Operating activities:Net loss
    
    $
    (4,871
    )
    
    $
    (6,295
    )Adjustments to reconcile net loss to net cash used for operating activities:Depreciation and amortization
    
    
    
    
    
    
    110Gain on write-off/disposal of patents, property and equipment
    
    
    
    
    
    
    (326
    )Share-based compensation expense
    
    
    304
    
    
    
    2,033Settlement of accounts payable and accrued liabilities
    
    
    
    
    
    
    (1,880
    )Issuance of
Series C-1 Preferred Stock for services
    
    
    12
    
    
    
    Fair value of derivative liabilities upon issuance
    
    
    5,015
    
    
    
    Gain on adjustments to fair value of derivative liabilities
    
    
    (2,985
    )
    
    
    Change in operating assets and liabilities:Prepaids and other current assets
    
    
    436
    
    
    
    (469
    )Accounts
payable and accrued expenses
    
    
    (33
    )
    
    
    (4,045
    )Accrued payroll and related expenses
    
    
    (64
    )
    
    
    (1,421
    )Net cash used for operating activities
    
    
    (2,186
    )
    
    
    (12,293
    )Investing activities:Sales of short-term investments
    
    
    
    
    
    
    10,000Net proceeds from sale of patents and property and equipment
    
    
    
    
    
    
    836Additions to property and equipment
    
    
    
    
    
    
    (18
    )Increase in patent costs and other assets
    
    
    
    
    
    
    (6
    )Net cash provided by investing activities
    
    
    
    
    
    
    10,812Financing activities:Proceeds from issuance of derivative obligations
    
    
    6,003
    
    
    
    Net proceeds from issuance of Series B Preferred Stock
    
    
    
    
    
    
    6,810Payments on credit facility
    
    
    
    
    
    
    (5,933
    )Payments on obligations under notes payable
    
    
    
    
    
    
    (331
    )Payments on obligations under capital leases
    
    
    
    
    
    
    (3
    )Net cash provided by financing activities
    
    
    6,003
    
    
    
    543Net increase (decrease) in cash and cash equivalents
    
    
    3,817
    
    
    
    (938
    )Cash and cash equivalents at beginning of period
    
    
    4,254
    
    
    
    9,447Cash and cash equivalents at end of period
    
    $
    8,071
    
    
    $
    8,509Supplemental schedule of noncash investing and financing activities:Issuance of common stock at par value, offset by paid-in capital reduction
    
    
    290
    
    
    
    Accrued
dividends payable in Series C-1 Preferred Stock
    
    
    87
    
    
    
    
   3




---



##### Table of Contents



LA JOLLA PHARMACEUTICAL COMPANY
 
 Notes to Condensed Consolidated Financial Statements
  June 30, 2010
 1. Basis of Presentation
   Significant 2010 Events
    4




---



##### Table of Contents



Significant 2009 Events
 ®
    5




---



##### Table of Contents



2. Accounting Policies
 Principles of Consolidation
  Use of Estimates
  Recent Accounting Pronouncements
  Revenue Recognition
 ASC Topic on Revenue
Recognition
  Impairment of Long-Lived Assets
    6




---



##### Table of Contents



Accrued Clinical/Regulatory Expenses
   Net Loss Per Share
   Derivative Liabilities
    7




---



##### Table of Contents



3. Fair Value of Financial Instruments
  
    
    Level 1  Quoted prices in active markets for identical assets or liabilities.
    
    Level 2  Inputs other than Level 1 that are observable, either directly or
indirectly, such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are observable or
can be corroborated by observable market data for substantially the full term
of the assets or liabilities.
    
    Level 3  Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the assets or
liabilities.
    Fair Value Measurements at June 30, 2010Balance at
    
    
    Quoted Prices in
    
    
    Significant Other
    
    
    SignificantJune 30,
    
    
    Active Markets
    
    
    Observable Inputs
    
    
    Unobservable Inputs2010
    
    
    (Level 1)
    
    
    (Level 2)
    
    
    (Level 3)Embedded derivative
liabilities
    
    $
    4,895
    
    
    $
    
    
    
    $
    
    
    
    $
    4,895Warrant derivative liabilities
    
    
    3,208
    
    
    
    
    
    
    
    
    
    
    
    3,208Total
    
    $
    8,103
    
    
    $
    
    
    
    $
    
    
    
    $
    8,103
  8




---



##### Table of Contents



Fair Value Measurements Using SignificantUnobservable Inputs (Level 3)Embedded Derivative
    
    
    Warrant DerivativeLiabilities
    
    
    Liabilities
    
    
    TotalBeginning balance at December 31, 2009
    
    $
    
    
    
    $
    
    
    
    $
    Issuances
    
    
    5,524
    
    
    
    5,494
    
    
    
    11,018Adjustments to estimated fair value
    
    
    (699
    )
    
    
    (2,286
    )
    
    
    (2,985
    )Accrued
dividends payable in Series C-1 Preferred
    
    
    70
    
    
    
    
    
    
    
    70Transfers into Level 3
    
    
    
    
    
    
    
    
    
    
    Ending balance at June 30, 2010
    
    $
    4,895
    
    
    $
    3,208
    
    
    $
    8,103
 4. Development and Stock Purchase Agreements
      9




---



##### Table of Contents



5. Securities Purchase Agreement
   Allocation of Proceeds
  Common Stock
  Accounting Treatment
  Redeemable Preferred Stock
  Voting Rights
  Dividends
   10




---



##### Table of Contents



Conversion Rights
   Liquidation Preference
  Redemption Rights
    11




---



##### Table of Contents



Restrictions
  Accounting Treatment
       12




---



##### Table of Contents



Derivative Liabilities
   Accounting Treatment
    Fair Value Measurements atMay 26, 2010
    
    
    June 30, 2010Embedded Derivatives of Series C-1 Preferred
    
    $
    5,524
    
    
    $
    4,825Embedded
Derivatives of accrued dividends payable in Series C-1
Preferred
    
    
    
    
    
    
    70Series D-1 Warrants
    
    
    815
    
    
    
    497Series C-2 Warrants for:Series C-2 Preferred
    
    
    3,049
    
    
    
    1,717Series D-2 Warrants
    
    
    1,630
    
    
    
    994$
    11,018
    
    
    $
    8,103
   13




---



##### Table of Contents



May 26, 2010
    
    
    June 30, 2010Closing
price per share of common stock
    
    $
    0.061
    
    
    $
    0.046Estimated fair value per
share of common stock
(after related discounts)
    
    $
    0.010
    
    
    $
    0.007Conversion price per share
    
    $
    0.015
    
    
    $
    0.015Volatility
    
    
    109.2
    %
    
    
    109.2
    %Risk-free interest rate
    
    
    2.68
    %
    
    
    2.42
    %Credit spread
    
    
    17.3
    %
    
    
    17.6
    %Remaining
expected lives of underlying securities (years)
    
    
    6.9
    
    
    
    6.8
   May 26, 2010
    
    
    June 30, 2010Closing
price per share of common stock
    
    $
    0.061
    
    
    $
    0.046Estimated fair value per
share of common stock
(after related discounts)
    
    $
    0.010
    
    
    $
    0.007Conversion price per share
    
    $
    0.015
    
    
    $
    0.015Volatility
    
    
    84.4
    %
    
    
    84.4
    %Risk-free interest rate
    
    
    1.28
    %
    
    
    1.00
    %Remaining
expected lives of underlying securities (years)
    
    
    3.3
    
    
    
    3.3
   14




---



##### Table of Contents



May 26, 2010
    
    
    June 30, 2010Closing
price per share of common stock
    
    $
    0.061
    
    
    $
    0.046Estimated fair value per
share of common stock
(after related discounts)
    
    $
    0.010
    
    
    $
    0.007Conversion price per share
    
    $
    0.015
    
    
    $
    0.015Volatility
    
    
    109.2
    %
    
    
    109.2
    %Risk-free interest rate
    
    
    2.68
    %
    
    
    2.42
    %Credit spread
    
    
    17.3
    %
    
    
    17.6
    %Remaining
expected lives of underlying securities (years)
    
    
    6.9
    
    
    
    6.8
  6. Stockholders Equity
 Share-Based Compensation
      15




---



##### Table of Contents



Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,2010
    
    
    2009
    
    
    2010
    
    
    2009Research and development
    
    $
    
    
    
    $
    566
    
    
    $
    
    
    
    $
    632General and administrative
    
    
    81
    
    
    
    925
    
    
    
    304
    
    
    
    1,402Share-based compensation
expense included in
operating expenses
    
    $
    81
    
    
    $
    1,491
    
    
    $
    304
    
    
    $
    2,034
   Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,Options:
    
    2010
    
    
    2009
    
    
    2010
    
    
    2009Risk-free interest rate
    
    
    2.6
    %
    
    
    
    
    
    
    2.6
    %
    
    
    0.6
    %Dividend yield
    
    
    0.0
    %
    
    
    
    
    
    
    0.0
    %
    
    
    0.0
    %Volatility
    
    
    106.5
    %
    
    
    
    
    
    
    106.5
    %
    
    
    295.0
    %Expected life (years)
    
    
    5.8
    
    
    
    
    
    
    
    5.8
    
    
    
    5.6
 Three and Six MonthsEndedJune 30,ESPP:
    
    2010
    
    
    2009Risk-free interest rate
    
    
    0.2
    %
    
    
    Dividend yield
    
    
    0.0
    %
    
    
    Volatility
    
    
    90.5
    %
    
    
    Expected life (months)
    
    
    3
    
    
    
    
   16




---



##### Table of Contents



Outstanding OptionsWeighted-AverageNumber of
    
    
    ExerciseShares
    
    
    PriceBalance at December 31, 2009
    
    
    3,508,568
    
    
    $
    6.99Granted
    
    
    6,700,000
    
    
    $
    0.06Forfeited / Expired
    
    
    (875,215
    )
    
    $
    4.41Balance at June 30, 2010
    
    
    9,333,353
    
    
    $
    2.25
 Restricted Stock Units
    Weighted-AverageGrant DateNumber of
    
    
    Fair ValueShares
    
    
    per ShareRestricted stock units outstanding at December 31, 2009
    
    
    2,021,024
    
    
    $
    0.17Cancelled
    
    
    (2,021,024
    )
    
    $
    0.17Restricted stock units outstanding at June 30, 2010
    
    
    
    
    
    $
    
 7. Restructuring Costs
   17




---



##### Table of Contents



8. Commitments and Contingencies
    18




---



##### Table of Contents



ITEM 2.
    
    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 Forward-Looking Statements
  Overview and Recent Developments
      19




---



##### Table of Contents




    
    Develop, sell or out-license our Riquent program, although we may not receive any
significant value upon such a sale or license; and
 
    
    Pursue potential other strategic transactions, which could include mergers, license
agreements or other collaborations, with third parties where we seek new compounds for
development and seek additional capital.
    
    
    In January 2009 we entered into a development and commercialization agreement (the
Development Agreement) with BioMarin CF Limited (BioMarin CF), a wholly-owned
subsidiary of BioMarin Pharmaceutical Inc. (BioMarin Pharma) for which we received a
non-refundable commencement payment of $7.5 million pursuant to the Development
Agreement from BioMarin CF and $7.5 million from BioMarin Pharma in exchange for a
newly designated series of our preferred stock pursuant to the securities purchase
agreement. Following the futile results of the first interim efficacy analysis of
Riquent received in February 2009, the Development Agreement was terminated on March 27, 2009 and all of the
Companys Series B-1 preferred shares purchased by BioMarin Pharma were converted into
common shares. Additionally, all rights to Riquent were returned to us.
 
    
    In February 2009, an Independent Monitoring Board for the Riquent Phase 3 ASPEN
study informed us that, per its review of the first interim efficacy analysis of
Riquent, continuing the study was futile. We subsequently unblinded the data and found
that there was no statistical difference in the primary endpoint, delaying time to
renal flare, between the Riquent-treated group and the placebo-treated group, although
there was a significant difference in the reduction of antibodies to double-stranded
DNA. There were 56 renal flares in 587 patients treated with either 300-mg or 900-mg
of Riquent, and 28 renal flares in 283 patients treated with placebo.
  
    
    In October 2009, we attempted to obtain stockholder approval for a Plan of Complete
Liquidation and Dissolution but the majority of our stockholders failed to return
their proxy cards or otherwise indicate their votes with respect to this proposal.
Accordingly, we were not able to obtain the requisite quorum to conduct business at
the special meeting and were therefore unable to proceed with dissolution.
  20




---



##### Table of Contents




    
    In December 2009, we entered into an Agreement and Plan of Reorganization (the
Merger Agreement) by and among the Company, Jewel Merger Sub, Inc. and Adamis
Pharmaceuticals Corporation (Adamis). The transaction contemplated by the Merger
Agreement was structured as a reverse merger, in which Jewel Merger Sub,
Inc., a wholly-owned subsidiary of the Company, would merge with and into Adamis, with
Adamis surviving (the Merger). On March 3, 2010, the Company and Adamis agreed to
terminate the Merger Agreement as the majority of our stockholders failed to return
their proxy cards or otherwise indicate their votes with respect to the proposals
related to the Merger. Accordingly, we were not able to obtain the requisite quorum to
conduct business at the special meeting. The solicitation of further votes was
cancelled due to the delisting of our common stock from Nasdaq on March 4, 2010.
 Critical Accounting Policies and Estimates
   Derivative Liabilities
   Alternative models could have been
selected to calculate these fair values, which may have produced significantly
different results. If we adopt a different valuation model in the future, this
may result in a lack of consistency between periods and materially affect our
fair value estimates. It may also result in a lack of comparability with other
companies that use different models, methods and assumptions. Additionally,
because the estimated fair values are affected by our stock price, fluctuations
in our stock price, which can be volatile, may significantly affect our
financial results. Recent Accounting Pronouncements
   21




---



##### Table of Contents



Results of Operations
        Liquidity and Capital Resources
    22




---



##### Table of Contents




    
    our ability to sell, out-license or otherwise develop our Riquent program; and
 
    
    our ability to consummate a strategic transaction such as a merger, license
agreement or other collaboration with a third party where we seek new compounds for
development and seek additional capital.
  Off-Balance Sheet Arrangements
  
 ITEM 4. CONTROLS AND PROCEDURES
   23




---



##### Table of Contents



PART II. OTHER INFORMATION
 
 ITEM 1A. Risk Factors
 I. RISK FACTORS RELATING TO LA JOLLA PHARMACEUTICAL COMPANY AND THE INDUSTRY IN WHICH WE OPERATE.
  We have only limited assets, no ongoing clinical trials and no products.
   Although we are attempting to pursue potential strategic transactions, there is no assurance that
we will be successful and, even if we are successful, our stockholders may suffer dilution or other
reductions in value as part of our acquisition of new assets.
   24




---



##### Table of Contents



Our ability to raise additional capital and enter into strategic transactions requires the approval
of certain investors from the May 2010 financing.
  The May 2010 financing has already caused, and will continue to cause, our existing stockholders to
suffer substantial dilution.
   25




---



##### Table of Contents



The recent delisting of our common stock could have a substantial effect on the price and liquidity
of our common stock.
   The price of our common stock has been, and will be, volatile and may continue to decline.
  
    
    limited financial resources;
    
    announcements regarding financings, mergers or other strategic transactions;
    
    future sales of significant amounts of our capital stock by us or our stockholders;
    
    developments in patent or other proprietary rights;
    
    developments concerning potential agreements with collaborators; and
    
    general market conditions and comments by securities analysts.
   26




---



##### Table of Contents



Our financial reporting is complicated and may confuse investors.
 Derivatives and Hedging Managements Discussion & Analysis of Financial Condition and
Results of Operations
  27




---



##### Table of Contents



ITEM 6. EXHIBITS
 ExhibitNumber
    
    Description3.1
    
    
    Certificate of Designations, Preferences and Rights of Series C-1
Convertible Preferred Stock, Series C-2 Convertible Preferred Stock,
Series D-1 Convertible Preferred Stock and Series D-2 Convertible
Preferred Stock (previously filed with the Companys Current Report on
Form 8-K filed May 28, 2010 and incorporated by reference herein)10.1
    
    
    Securities Purchase Agreement, dated as of May 24, 2010 by and among
the Company and the Purchasers named therein (previously filed with
the Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)10.2
    
    
    Form of Series C-2 Preferred Stock Purchase Warrant (previously filed
with the Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)10.3
    
    
    Form of Series D-1 Preferred Stock Purchase Warrant (previously filed
with the Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)10.4
    
    
    Form of Series D-2 Preferred Stock Purchase Warrant (previously filed
with the Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)10.5
    
    
    Chief Executive Officer Employment Agreement, dated as of May 24,
2010, by and between the Company and Deirdre Y. Gillespie, M.D.
(previously filed with the Companys Current Report on Form 8-K filed
May 28, 2010 and incorporated by reference herein)10.6
    
    
    Confidential Retention Agreement, dated as of May 24, 2010, by and
between the Company and Deirdre Y. Gillespie, M.D. (previously filed
with the Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)10.7
    
    
    Executive Employment Agreement, dated as of May 24, 2010, by and
between the Company and Gail A. Sloan (previously filed with the
Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)10.8
    
    
    Confidential Retention Agreement, dated as of May 24, 2010, by and
between the Company and Gail A. Sloan (previously filed with the
Companys Current Report on Form 8-K filed May 28, 2010 and
incorporated by reference herein)31.1
    
    
    Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2
    
    
    Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1
    
    
    Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  28




---



##### Table of Contents



SIGNATURES
  La Jolla Pharmaceutical CompanyDate:  August 20, 2010
    /s/ Deirdre Y. GillespieDeirdre Y. Gillespie, M.D.President and Chief Executive Officer
(On behalf of the Registrant)/s/ Gail A. SloanGail A. SloanChief Financial Officer and Secretary
(As Principal Financial and Accounting Officer)  29